Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.

MLA

Schlotter, Claus M., et al. “Ki67 and Lymphocytes in the Pretherapeutic Core Biopsy of Primary Invasive Breast Cancer: Positive Markers of Therapy Response Prediction and Superior Survival.” Hormone Molecular Biology & Clinical Investigation, vol. 32, no. 2, Nov. 2017, pp. 1–11. EBSCOhost, https://doi.org/10.1515/hmbci-2017-0022.

APA

Schlotter, C. M., Tietze, L., Vogt, U., Heinsen, C. V., & Hahn, A. (2017). Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival. Hormone Molecular Biology & Clinical Investigation, 32(2), 1–11. https://doi.org/10.1515/hmbci-2017-0022

Chicago

Schlotter, Claus M., Lothar Tietze, Ulf Vogt, Carlos Villena Heinsen, and Antje Hahn. 2017. “Ki67 and Lymphocytes in the Pretherapeutic Core Biopsy of Primary Invasive Breast Cancer: Positive Markers of Therapy Response Prediction and Superior Survival.” Hormone Molecular Biology & Clinical Investigation 32 (2): 1–11. doi:10.1515/hmbci-2017-0022.